Medidata Solutions Inc (NASDAQ:MDSO) was the target of some unusual options trading on Friday. Traders bought 846 call options on the company. This represents an increase of 1,310% compared to the typical volume of 60 call options.

Shares of Medidata Solutions (NASDAQ MDSO) opened at $67.20 on Wednesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.37 and a current ratio of 1.29. Medidata Solutions has a 12-month low of $47.77 and a 12-month high of $85.92. The company has a market capitalization of $3,930.00, a P/E ratio of 96.00, a P/E/G ratio of 3.47 and a beta of 1.69.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Thursday, October 26th. The company reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.02. The firm had revenue of $140.08 million during the quarter, compared to analysts’ expectations of $141.27 million. Medidata Solutions had a return on equity of 11.54% and a net margin of 7.84%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.28 earnings per share. analysts predict that Medidata Solutions will post 0.78 EPS for the current fiscal year.

In other news, CEO Tarek Sherif sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $68.76, for a total value of $13,752,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Rouven Bergmann sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $65.95, for a total value of $131,900.00. Following the completion of the sale, the chief financial officer now owns 89,775 shares of the company’s stock, valued at $5,920,661.25. The disclosure for this sale can be found here. Insiders sold 239,010 shares of company stock valued at $16,437,036 over the last 90 days. Company insiders own 5.80% of the company’s stock.

A number of large investors have recently modified their holdings of the business. 1st Global Advisors Inc. grew its holdings in Medidata Solutions by 0.5% in the 2nd quarter. 1st Global Advisors Inc. now owns 8,243 shares of the company’s stock valued at $645,000 after buying an additional 37 shares in the last quarter. Pinebridge Investments L.P. grew its holdings in Medidata Solutions by 2.1% in the 2nd quarter. Pinebridge Investments L.P. now owns 7,305 shares of the company’s stock valued at $572,000 after buying an additional 153 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Medidata Solutions by 10.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,186 shares of the company’s stock valued at $171,000 after buying an additional 208 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in Medidata Solutions by 0.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 82,279 shares of the company’s stock valued at $6,435,000 after buying an additional 526 shares in the last quarter. Finally, Bank of Nova Scotia grew its holdings in Medidata Solutions by 7.7% in the 2nd quarter. Bank of Nova Scotia now owns 8,365 shares of the company’s stock valued at $654,000 after buying an additional 600 shares in the last quarter.

MDSO has been the subject of a number of recent analyst reports. TheStreet cut Medidata Solutions from a “b” rating to a “c+” rating in a research report on Thursday, December 14th. Wells Fargo & Co dropped their price target on Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a research report on Friday, October 27th. Zacks Investment Research upgraded Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Friday, November 10th. SunTrust Banks reiterated a “buy” rating and set a $92.00 price target on shares of Medidata Solutions in a research report on Friday, October 27th. Finally, Deutsche Bank began coverage on Medidata Solutions in a research report on Friday, December 8th. They set a “buy” rating and a $78.00 price target for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $84.54.

TRADEMARK VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/medidata-solutions-sees-unusually-large-options-volume-mdso/1810063.html.

Medidata Solutions Company Profile

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.